A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Clinical trial NCT05735184 · RECRUITING

Trial details

NCT number: NCT05735184
Sponsor: Kura Oncology, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Mixed Lineage Leukemia Gene Mutation Refractory AML AML With Mutated NPM1 Acute Myeloid Leukemia Recurrent Acute Myeloid Leukemia, in Relapse NPM1 Mutation KMT2Ar Myeloid Sarcoma Nucleophosmin 1-mutated Acute Myeloid Leukemia

Start date: 2023-07-18
Primary completion: 2030-04-01
Enrollment: 420

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.